Exemestane
Alias: Aromasin; Exemestan
Appearance: White or Almost White Crystalline Powder
Product content: ≥ 99%
CAS:107868-30-4
Molecular formula: C20H24O2
Molecular Weight:296.40
Use: used in the treatment of metastatic breast cancer . and used as aid in the treatment of early breast cancer.
You may also hear it called Aromasin, which is its best-known brand name. There are a number of other brands of exemestane, all of which contain the same dose of the drug.
Exemestane is a drug used to treat breast cancer in women who have gone through the menopause. |
You may also hear it called Aromasin, which is its best-known brand name. There are a number of other brands of exemestane, all of which contain the same dose of the drug. |
Men with breast cancer may be given exemestane, although another drug called tamoxifen is more commonly used. |
Exemestane works by reducing the amount of oestrogen made in the body.
Some breast cancers are stimulated to grow by the hormone oestrogen. These are known as oestrogen receptor positive or ER+ breast cancers.
Exemestane belongs to a group of drugs called aromatase inhibitors.
Common side effects of exemestane include:
Aching or pain in the joints and muscles
menopausal symptoms
low mood and depression
difficulty sleeping
fatigue (extreme tiredness)
osteoporosis (thinning of the bone)
Other side effects of exemestane include:
headaches, nausea and vomiting
high cholesterol
loss of appetite
constipation or diarrhoea
carpal tunnel syndrome
hair and skin changes
vaginal bleeding
liver changes
More than 10 in every 100 people have one or more of these effects. Hot flushes and sweats - this happens in more than 1 in 5 women (22%) |
25 mg orally once a day
Comment:
-This drug should be administered after a meal.
Uses:
-Adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy.
-Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.